Pharma will be expensive, may outperform mkt: Sanjay Sinha

Sanjay Sinha, Founder at Citrus Advisors told CNBC-TV18, "If you look at pharmaceutical as a sector, the stock performances in the last one year has been more company specific than it has been for the case of the sector as a whole. This has come from the fact that there has been these company specific regulatory developments, which have at times stalled the rally in some of these stocks.""On a prospective basis, I feel that within the pharmaceuticals midcaps, you still have two of the opportunities which are still intact in an environment where the rupee is not likely to be ruling strong and the opportunity on the global front remains intact with many of the pharmaceutical companies do continue to hold value. They of course are more expensive elements within the market at this point of time but in a rallying market people also look for defensives and in that search, many times the valuations can get stretched in intermittent periods," he said."Therefore pharma would be one sector which will continue to be expensive, may be a slight outperformer to the broad market going forward," he said.